

COVID-19 S-clgG1 Cynomolgus monoclonal neutralizing antibody

Catalog: MB66245

Host: Cynomolgus

Reactivity: COVID-19

BackGround:

The cause of the COVID-19 pandemic is a novel and highly pathogenic coronavirus, termed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 is a member of the Coronaviridae family of viruses. The genome of SARS-CoV-2 is similar to other coronaviruses, and is comprised of four key structural proteins: S, the spike protein, E, the envelope protein, M, the membrane protein, and N, the nucleocapsid protein. Coronavirus spike proteins are class I fusion proteins and harbor an ectodomain, a transmembrane domain, and an intracellular tail. The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at S1/S2 and S2' sites. S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers. In humans, both SARS-CoV and SARS-CoV-2 spike proteins utilize the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry. Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors.

Product:

1 mg/ml. Cynomolgus IgG1. Liquid in 0.01M Phosphate Buffered Saline, pH 7.4.

Molecular Weight:

Swiss-Prot:

P0DTC2

Purification&Purity:

>95%, cultured in vitro under conditions free from animal

derived components.

Applications:

ELISA: Use at an assay dependent dilution.


Storage&Stability:

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.


Specificity:

Recognizes COVID-19 S Protein, COVID-19 S-RBD Protein and block ACE-2 receptor binding.

DATA:



Immobilized Recombinant COVID-19 S Protein RBD-SD1 at 5 ug/ml can bind Anti-COVID-19 S-clgG1 Neutralizing Antibody, the EC50 is less than 27.7 ng/ml.



Anti-COVID-19 S-clgG1 Neutralizing Antibody can block Recombinant Human ACE2 Protein and Recombinant COVID-19 S Protein RBD-SD1 interaction, the IC50 for this effect is 213 ng/ml.

Note:

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.

Add: 1660 South Highway 100, Suite 500 St. Louis Park, MN 55416, USA.

Email: info@bioworld.com

Tel: 6123263284

Fax: 6122933841

Bioworld technology, co. Ltd.

Add: No 9, weidi road Qixia District Nanjing, 210046, P. R. China.

Email: info@biogot.com

Tel: 0086-025-68037686

Fax: 0086-025-68035151



PRODUCT DATA SHEET

Bioworld Technology, Inc.

Bioworld Technology, Inc.

Add: 1660 South Highway 100, Suite 500 St. Louis Park,
MN 55416, USA.

Email: info@bioworld.com

Tel: 6123263284

Fax: 6122933841

Bioworld technology, co. Ltd.

Add: No 9, weidi road Qixia District Nanjing, 210046,
P. R. China.

Email: info@biogot.com

Tel: 0086-025-68037686

Fax: 0086-025-68035151